ArticlePloS one2022

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.

Judit Hodrea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.